Adalimumab biosimilar - Sandoz

Drug Profile

Adalimumab biosimilar - Sandoz

Alternative Names: GP-2017

Latest Information Update: 17 Feb 2017

Price : $50

At a glance

  • Originator Sandoz
  • Class Anti-inflammatories; Anti-TNF monoclonal antibodies; Antipsoriatics; Antirheumatics
  • Mechanism of Action Immunomodulators; Tumour necrosis factor alpha inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Plaque psoriasis; Rheumatoid arthritis

Most Recent Events

  • 15 Dec 2016 Pharmacodynamics data from a preclinical studies in Arthritis presented at the 24th United European Gastroenterology Week (UEGW-2016)
  • 11 Nov 2016 Pharmacokinetics, adverse events and immunogenicity data from a phase I trial in Healthy volunteers presented at 80th American College of Rheumatology and the 51st Annual Meeting of the Association of Rheumatology and Health Professionals
  • 11 Nov 2016 Sandoz completes a phase I trial in Healthy volunteers in Germany
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top